IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: JIA

SERIAL NO.: 10/817,330

EXAMINER: WINSTON, R.O.

FILED: APRIL 02, 2004) ART UNIT: 1655

TITLE: FORMULATION OF DUAL CYCLOXYGENASE (COX) AND LIPOXYGENASE (LOX)

INHIBITORS FOR MAMMAL SKIN CARE

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application. In accordance with 37 CFR § 1.98(a)(3)(i) the relevance of JP 361238719 is set forth in its abstract, the English translation of which is provided.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action on the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117

Respectfully submitted,

Date: June 23, 2010 /Rosemary Kellogg/

Rosemary Kellogg, #39,726 Swanson & Bratschun, L.L.C. 8210 SouthPark Terrace Littleton, Colorado 80120 Telephone: (303) 268-0066 Facsimile: (303) 268-0065

S:\ClientFolders\0062 (UniGen Pharmaceuticals)\26\UTILITY\IDS21.doc